Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

728
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
728
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

7.9K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
7.9K
Hematopoiesis01:21

Hematopoiesis

8.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-Frequency <i>PPM1D</i> Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma.

Cancers·2026
Same author

Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma.

Cancers·2026
Same author

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same author

Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort.

British journal of haematology·2026
Same author

Influence of <i>PPM1D</i> Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients.

Biomedicines·2026
Same author

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Bone marrow transplantation·2026

Related Experiment Video

Updated: Dec 20, 2025

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.1K

Current concepts and future directions for hemato-oncologic diagnostics.

Johanna Flach1, Evgenii Shumilov2, Raphael Joncourt3

  • 1Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.

Critical Reviews in Oncology/Hematology
|May 24, 2020
PubMed
Summary

Precision diagnostics in hemato-oncology are rapidly evolving with new technologies like next-generation sequencing (NGS) and targeted therapies. These advancements improve acute myeloid leukemia treatment but raise questions about minimal residual disease monitoring.

Keywords:
Acute lymphatic leukemia (ALL)Acute myeloid leukemia (AML)Hemato-oncologic diagnosticsLiquid biopsyLymphomasMultiple myelomaNext-generation sequencing (NGS)Novel technologies

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.2K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K

Related Experiment Videos

Last Updated: Dec 20, 2025

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.1K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.2K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Diagnostics

Background:

  • Hemato-oncologic diagnostics are undergoing significant transformation.
  • Novel technologies like next-generation sequencing (NGS) and digital droplet PCR are being integrated into routine diagnostics for myeloid and lymphatic malignancies.
  • Liquid biopsy is emerging as a tool for lymphoid malignancies.

Purpose of the Study:

  • To review current dynamic changes in hemato-oncologic diagnostics.
  • To discuss the challenges posed by new technologies and targeted therapies.
  • To highlight future directions in hemato-oncologic diagnostics over the next 5-10 years.

Main Methods:

  • Review of current literature and clinical practice trends.
  • Exploration of novel diagnostic technologies (NGS, ddPCR, liquid biopsy).
  • Discussion of targeted therapies (e.g., FLT3, IDH1/IDH2 inhibitors) and their diagnostic implications.

Main Results:

  • Increasing demand for hematologic precision diagnostics at initial diagnosis and during disease course.
  • Crucial role of short turn-around times in diagnostics.
  • NGS offers potential for minimal residual disease diagnostics, but requires optimization for sensitivity, timing, and intervention thresholds.

Conclusions:

  • Hemato-oncologic diagnostics are rapidly advancing with new technologies and precision therapies.
  • Challenges exist in implementing and optimizing novel diagnostic approaches, particularly for minimal residual disease.
  • Future directions point towards further integration of molecular diagnostics and targeted therapies for improved patient outcomes.